News Quantified

MCRB – seres therapeutics, inc. (US:NASDAQ)

Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.

3/12

07:00 am

mcrb

Low

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]

Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}